Evidence map›Paper›PMID 35778364›Full record

ReviewEuropean urology focus2022

Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States.

Folawiyo Laditi, James Nie, Tashzna Jones, Michael S Leapman

Abstract readReview
PubMed Publisher
In one paragraph

Review in European urology focus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Role of radiomic analysis of [European radiology · 2023
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Folawiyo LaditiYale University School of Medicine, New Haven, CT, USA.
James NieYale University School of Medicine, New Haven, CT, USA.
Tashzna JonesYale University School of Medicine, New Haven, CT, USA; Department of Urology, Yale School of Medicine, New Haven, CT, USA.
Michael S LeapmanYale University School of Medicine, New Haven, CT, USA; Department of Urology, Yale School of Medicine, New Haven, CT, USA. Electronic address: michael.leapman@yale.edu.

Funding

Understanding the Adoption and Impact of New Risk Assessment Technologies in Prostate Cancer CareK08CA237872 · NCI · YALE UNIVERSITY · PI LEAPMAN, MICHAEL STUART · 2019 to 2023
$1.1M
NCI NIH HHS K08 CA237872
6 · The paper itself

Abstract

In this review we summarize evidence from US studies examining variation in the use of prostate magnetic resonance imaging (MRI) and tissue-based gene expression tests (genomic tests), focusing on sources of regional and racial variation. Large observational studies indicate that prostate MRI and genomic testing vary significantly at the regional level as measured across multiple geographic boundaries. Similarly, there is lower use of prostate MRI among Black versus White-identified patients Black in comparison to those who are White, as well as evidence of less use among Hispanic and Asian versus White patients. These findings indicate opportunities to address modifiable sources of practice variation in localized prostate cancer. PATIENT SUMMARY: In this review, we found that use of prostate magnetic resonance imaging (MRI) scans and genetic testing differed by region, and race, with less prostate MRI use among Black versus White patients. These findings can help raise awareness about gaps in access to new prostate cancer tools.

Indexed as

Prostatic NeoplasmsWhite PeopleBlack or African AmericanHispanic or LatinoHumansMaleRisk AssessmentUnited StatesDisparityGenomic testingProstate cancerProstate magnetic resonance imaging

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.